Icariin

CAT:
804-HY-N0014-01
Size:
100 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Icariin - image 1

Icariin

  • Description:

    Icariin is a flavonol glycoside. Icariin inhibits PDE5 and PDE4 activities with IC50s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.
  • Product Name Alternative:

    Ieariline
  • UNSPSC:

    12352005
  • Hazard Statement:

    H315, H319, H335
  • Target:

    Autophagy; Phosphodiesterase (PDE) ; PPAR
  • Type:

    Natural Products
  • Related Pathways:

    Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
  • Applications:

    COVID-19-anti-virus
  • Field of Research:

    Inflammation/Immunology; Cardiovascular Disease; Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/Icariin.html
  • Purity:

    99.06
  • Solubility:

    DMSO : 125 mg/mL (ultrasonic)
  • Smiles:

    O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC2=C(C/C=C(C)/C)C(OC(C3=CC=C(OC)C=C3)=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)C5=O)=C5C(O)=C2)[C@@H]1O
  • Molecular Formula:

    C33H40O15
  • Molecular Weight:

    676.66
  • Precautions:

    H315, H319, H335
  • References & Citations:

    [1]Xin ZC, et al. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5 (1) :15-8.|[2]Lu YF, et al. Icariin is a PPARα activator inducing lipid metabolic gene expression in mice. Molecules. 2014 Nov 6;19 (11) :18179-91.|[3]Hu Y, et al. Effects and mechanisms of icariin on atherosclerosis. Int J Clin Exp Med. 2015 Mar 15;8 (3) :3585-9.|[4]Chen M, et al. Effects of icariin on reproductive functions in male rats. Molecules. 2014 Jul 3;19 (7) :9502-14.|[5]Liu D, et al. Icariin protects rabbit BMSCs against OGD-induced apoptosis by inhibiting ERs-mediated autophagy via MAPK signaling pathway. Life Sci. 2020 Apr 26:117730.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category:

    Natural Products
  • Clinical Information:

    Phase 3
  • Isoform:

    PDE4; PDE5; PPARα
  • CAS Number:

    489-32-7